Biogen, Inc.

( )
BIIB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. -1.97%73.511.0%$1711.84m
AMGNAmgen, Inc. -0.45%218.211.3%$927.01m
REGNRegeneron Pharmaceuticals, Inc. 0.12%512.962.6%$847.29m
BIIBBiogen, Inc. 1.29%321.051.5%$816.11m
VRTXVertex Pharmaceuticals, Inc. -1.22%246.611.9%$649.45m
ILMNIllumina, Inc. 2.36%287.623.5%$503.42m
MRNAModerna, Inc. -1.73%31.860.0%$501.83m
ALXNAlexion Pharmaceuticals, Inc. -2.36%96.232.0%$301.82m
AAgilent Technologies, Inc. 2.14%78.331.6%$233.31m
INCYIncyte Corp. -1.07%86.812.5%$218.68m
EXASEXACT Sciences Corp. 1.04%67.0621.0%$184.03m
SGENSeattle Genetics, Inc. 0.54%120.326.1%$162.16m
BMRNBioMarin Pharmaceutical, Inc. -0.06%79.554.3%$150.47m
NVAXNovavax, Inc. -0.76%17.05114.7%$134.63m
IMMUImmunomedics, Inc. 6.57%19.6411.9%$129.09m

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.